This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Drug Development Advisory Firm Rosa & Co. LLC To Present Two Mechanistic Modeling Presentations At The 28th JSSX Conference

SAN CARLOS, Calif., Oct. 4, 2013 /PRNewswire/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that Dr. Mike Reed, Chief Scientist, and Dr. Christina Friedrich, Chief Engineer, will present at the Japanese Society for the Study of Xenobiotics, JSSX Annual Meeting ( October 9 th – 11 th), Tokyo, Japan. Dr. Reed's talk, entitled "Application of Mechanistic Physiological Modeling in the Drug Development Process – Overview and Case Studies", will introduce key features of mechanistic physiological models (also known as quantitative systems pharmacology or PhysioPD™ models), which are deployed in Rosa's practice. Dr. Reed will use multiple case studies to illustrate the application and impact of mechanistic models in drug discovery and development. Dr. Friedrich's seminar, entitled "Introduction of a Model Qualification Method (MQM) to foster model-based drug development in the exploratory phase of R&D" will outline the procedures and key qualification criteria of Rosa's MQM. Dr. Friedrich will describe the motivation behind each criterion and its role in confirming that a model is fit for purpose; examples will illustrate how the MQM approach ensures a successful modeling project.

(Logo: http://photos.prnewswire.com/prnh/20131004/PH91999LOGO )

"We are honored to have the opportunity to speak at this very prestigious meeting," said Dr. Ron Beaver, Rosa's President and CEO.

About Rosa

Rosa helps clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of R&D related challenges, Rosa offers customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these capabilities, Rosa's clients participate in customized model creation, testing, and research simulations, retain the models, and acquire the ability to perform model research to inform decisions and better understand implications for their drug development programs. Rosa's staff has unparalleled professional experience in applying modeling and simulation to accelerate drug development and have completed hundreds of engagements with clients in virtually all therapeutic areas. The Rosa team is unique in its breadth and depth of disease area experience, including metabolic diseases, oncology, inflammation, immune dysfunction, CNS, dermatology, and antibacterial/antiviral biology. For more information, visit www.rosaandco.com.

Press Contact: Rebecca Baillie 530-661-7476

Read more news from Rosa & Co. LLC

SOURCE Rosa & Co. LLC

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,640.56 +25.75 0.16%
S&P 500 1,947.15 +5.87 0.30%
NASDAQ 4,430.7050 +11.2270 0.25%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs